Anzeige
Mehr »
Login
Freitag, 01.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Neuer Gold Rekord bei knapp 2.800 USD und Übernahme-Zirkus!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0CA8A | ISIN: US3184571087 | Ticker-Symbol:
1-Jahres-Chart
FIRST ACCEPTANCE CORPORATION Chart 1 Jahr
5-Tage-Chart
FIRST ACCEPTANCE CORPORATION 5-Tage-Chart
ACCESSWIRE
248 Leser
Artikel bewerten:
(1)

First Acceptance Corporation Reports Operating Results for the Three and Six Months Ended June 30, 2024

NASHVILLE, TN / ACCESSWIRE / August 13, 2024 / First Acceptance Corporation (OTCQX:FACO) today reported its financial results for the three and six months ended June 30, 2024. A quarterly report can be found at www.otcmarkets.com/stock/FACO/disclosure.

Income before income taxes, for the three months ended June 30, 2024 was $8.1 million, compared with $4.2 million for the three months ended June 30, 2023. Net income for the three months ended June 30, 2024 was $5.8 million, compared $3.2 million for the three months ended June 30, 2023. Diluted net income per share was $0.15 for the three months ended June 30, 2024, compared with $0.08 for the same period in the prior year.

Income before income taxes, for the six months ended June 30, 2024 was $17.0 million, compared with $5.6 million for the six months ended June 30, 2023. Net income for the six months ended June 30, 2024 was $12.7 million, compared with $4.3 million for the six months ended June 30, 2023. Diluted net income per share was $0.33 for the six months ended June 30, 2024, compared with $0.11 for the same period in the prior year.

For the three months ended June 30, 2024, we recognized unfavorable prior period loss and LAE development of $4.8 million, compared with favorable prior period loss and LAE development of $0.1 million for the same period in the prior year. For the six months ended June 30, 2024, we recognized $8.8 million of unfavorable prior period loss and LAE development compared with $0.7 million for the same period in the prior year.

The Company's President and Chief Executive Officer, Ken Russell, commented "The quarter ended June 30, 2024 marks the Company's sixth consecutive profitable quarter reflecting a steady continuation of the favorable market trends we have experienced since the fourth quarter of 2022. Since then, premium growth has sustained across all our distribution channels through a combination of rate increases and increased production. Throughout, our loss ratio has remained within our expectations, as has our expense ratio, which was favorably impacted by the sale of our insurance agency operations in December 2023. Investment income has also grown to become a more significant component of our net income. Going forward, I remain confident that our Company is well positioned to continue this profitable success ".

About First Acceptance Corporation

First Acceptance Corporation is an insurance holding company headquartered in Nashville that underwrites non-standard personal automobile insurance through insurance companies known as the First Acceptance Insurance Group.

Additional information about First Acceptance Corporation can be found online at www.firstacceptance.com.

Forward-Looking Statements

This press release contains forward-looking statements. All statements made other than statements of historical fact are forward-looking statements. You can identify these statements from our use of the words "believe," "expect," "look," or the negative of these objective terms and similar expressions. These statements, which have been included in reliance on the "safe harbor" provisions of the federal securities laws, involve risks and uncertainties. Investors are hereby cautioned that these statements may be affected by important factors, including, among others, the factors set forth under the caption "Risk Factors" in our Annual Report for the year ended December 31, 2023, filed by the Company with the OTCQX. Except as required by law, we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

First Acceptance Corporation and Subsidiaries
Condensed Consolidated Statements of Income
(amounts in thousands, except per share data)

Three Months Ended

Six Months Ended

June 30,

June 30,

2024

2023

2024

2023

Revenues

$

157,675

$

112,645

$

302,939

$

210,555

Income before income taxes

$

8,079

$

4,198

$

17,017

$

5,616

Net income

$

5,789

$

3,154

$

12,717

$

4,312

Net income per diluted share

$

0.15

$

0.08

$

0.33

$

0.11

Average diluted shares outstanding

38,987

38,211

38,898

38,119

Combined Ratio for Insurance Companies:

Loss

72.4

%

69.7

%

71.3

%

72.3

%

Expense

27.5

%

30.5

%

26.8

%

29.0

%

Combined

99.9

%

100.2

%

98.1

%

101.3

%

Book Value per Common Share

$

4.01

$

1.83

INVESTOR RELATIONS CONTACT:
Michael J. Bodayle
mbodayle@firstacceptance.com

SOURCE: First Acceptance Corporation



View the original press release on accesswire.com

© 2024 ACCESSWIRE
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.